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Introduction
Breast cancer stem cells (CSCs) are increasingly thought 
to play a major role in breast cancer growth and the 
formation of metastases. CSCs have hierarchical poten-
tial to undergo self-renewal along with yielding daughter 
cells that result in the formation of bulk tumor cells, 
while maintaining a self-replicating potential [1]. CSCs 
appear to make up a small minority of most tumors, 
while in others (for example, melanoma) they may 
comprise up to 25% of the total mass [2].
Epithelial-to-mesenchymal transition (EMT), a process 
ﬁ   rst noted during embryogenesis, guides the trans  for-
mation of non-mobile epithelial-like cells into mobile, 
mesenchymal-like cells that have the potential to travel to 
distant anatomical sites within the developing embryo 
(Figure 1). Th   is naturally occurring process has also been 
observed during tumor formation, and may lead to the 
development of metastatic growth. Th  e process can be 
reversed through mesenchymal-to-epithelial transition 
(MET), where migratory cells become anchored at 
distant sites and lose their migratory potential.
Embryonic signaling pathways, such as the Notch, 
Hedge  hog (Hh), Wnt, and transforming growth factor 
(TGF)-β pathways, are essential for stem cell signaling 
during embryogenesis [3]. Th  ese pathways play critical 
roles in normal tissue development and maintenance, 
and are also involved in the tight regulation of EMT. 
Deregulation of embryonic signaling pathways has been 
widely reported in human cancers, including breast, 
pancreatic, and lung [4-6]. Th   is observation has led to the 
evaluation of these pathways as potential targets for a 
new generation of anti-cancer drugs.
Th   is review examines current ﬁ  ndings and perspectives 
on the interplay between CSCs, embryonic signaling 
pathways, and EMT/MET in breast tumor growth and 
metastasis.
Breast cancer stem cells
Th  e cell-of-origin for breast CSCs has yet to be deter-
mined, but may be the result of malignant trans  for  mation 
of normal stem/progenitor cells [7]. Th   e long life span of 
stem/progenitor cells makes them more susceptible to 
the accumulation of DNA mutations. Th  e capacity to 
replicate and produce multiple progeny also makes stem 
and progenitor cells likely candidates for tumor cells-of-
origin [8].
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© 2011 BioMed Central LtdBRCA1 is known to play a role in the repair of double-
stranded DNA breaks in breast tissue, thereby main-
taining chromosomal stability and structure [9]. BRCA1 
expression is required for the diﬀ  erentiation of estrogen 
receptor (ER-) stem/progenitor cells into ER+ luminal 
cells. Loss of the double-stranded DNA break repair 
function, seen in BRCA1 deﬁ  cient or mutant cells, may 
contribute to the accumulation of genetically unstable 
breast stem cells, providing a source of cells suitable for 
carcinogenesis and CSC development [10].
Breast CSCs capable of forming mammospheres were 
isolated from pleural eﬀ   usions from breast cancer 
patients, and were tumorigenic when transplanted into 
SCID mice [11]. Breast CSCs expressed CD44, but had 
low or undetectable levels of CD24 and were lineage 
negative (CD44+CD24-/low/lin-) by ﬂ   ow cytometry [12]. 
NOD/SCID mice injected with as few as 200 ESA+ CD44+
CD24-/low cells formed tumors that could be serially 
passaged  in vivo. More recently, additional markers, 
includ  ing aldehyde dehydrogenase (ALDH)1, CD133 
(prominin-1) [13], CD49f hi and ITGA6 [14], have been 
proposed as breast CSC biomarkers. ALDH1, a detoxi-
fying enzyme that oxidizes intracellular aldehydes, is 
found in both normal mammary stem cells and breast 
cancer stem cell populations [15]. As few as 500 ALDH1+
breast tumor cells were capable of forming tumors when 
transplanted into NOD/SCID mice. An exami  nation of 
ALDH expression in human breast cancer found that 
ALDH1+ tumors were associated with HER2 expression, 
and the absence of ER and progesterone receptor 
expression (HER2+, ER-, PR-). ALDH-1 expres  sion in 
basal-type breast cell lines, but not most luminal cell 
lines, has been associated with a poor prognosis and 
decreased overall survival [16].
Signiﬁ  cantly, these biomarkers are not expressed uni-
ver  sally across all types of breast cancer CSCs, but rather 
are expressed diﬀ  erentially according to subtype [13,16]. 
In addition to histologic phenotype, biomarker expres-
sion may also be dependent upon the tumor micro-
environment [17]. For example, the micro  environ  ment 
Figure 1. Epithelial-to-mesenchymal transition, mesenchymal-to-epithelial transition, and the migration of cancer stem cells. In the 
presence of stimulatory signaling (that is, Hedgehog (Hh), Notch, Wnt, transforming growth factor (TGF)-β) primary tumor cells may undergo 
epithelial-to-mesenchymal transition (EMT), a process where cells suppress E-cadherin expression and lose their tight membrane junctions. Cells 
can acquire a mobile phenotype and migrate into the circulatory system by entering capillary beds. Exiting the circulatory system at a distant 
anatomical site, cells undergo the reverse process of mesenchymal-to-epithelial transition (MET), reacquiring their original non-mobile epithelial-
like phenotype.
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Page 2 of 11may provide regulatory signals that modulate the activity 
of transcription factors and subsequent gene expression. 
Th  e CSC microenvironment may also provide essential 
factors that help regulate EMT and MET processes and 
expression of resulting cellular phenotypes.
Treatment-resistant CD44+/CD24-/low cells
Th  e enrichment of CD44+/CD24-/low cells in primary 
breast tumors following chemotherapy suggests an innate 
resistance to standard treatments [18]. Th  e presence of 
ATP-binding cassette (ABC) trans  porters, including 
ABCG2, ﬁ  rst cloned by Doyle and colleagues, is highly 
expressed in a subpopulation (that is, side population) of 
CSCs [19,20]. ABC transporters act to confer resistance 
to chemotherapeutic agents by extrud  ing these com-
pounds out of the cell [21].
Similarly, enrichment of CD44+/CD24-/low cells has been 
demonstrated following treatment with radiation therapy 
[22]. Th   ese cells were capable of reproducing in an in vivo 
model following at least four generations of xenograft 
transplanted mice [23], suggesting that they play impor-
tant roles in tumor relapse and metastasis. Poten  tial 
mechanisms of chemotherapy and radiation resis  tance in 
breast cancer include the presence of lower concen-
trations of reactive oxygen species [24], cell dormancy, 
eﬃ   cient DNA repair mechanisms [25], and over  expres-
sion of Wnt/β-catenin and Notch signaling [22,26]. 
Treatment-resistant CD44+/CD24-/low cells, being poten-
tial cells-of-origin for metastatic growth, are currently 
being evaluated as therapeutic targets.
Th  e stem cell niche may also furnish CSCs with a 
means to evade chemotherapy through the presence of a 
Figure 2. Cross-talk among embryonic signaling pathways and experimental inhibitors. Potential cross-talk among embryonic signaling 
pathways (transforming growth factor (TGF)-β, Hedgehog (Hh), Notch, Wnt, and ErbB) is shown. The expansive potential for signaling cross-talk 
suggests that signaling pathways do not function in isolation, but instead are parts of a complex signaling network. Cross-talk can lead to both 
enhancing and inhibitory interactions between pathways. The actions of experimental pathway inhibitors are shown in yellow. Positive interactions 
are shown in green, while negative interactions are shown in red.
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plex microenvironment that is actively involved in stem 
cell growth. Th  e niche acts to shelter stem cells from 
apoptotic signals, diﬀ   erentiation stimuli, and environ-
men  tal insults [28]. Bidirectional signaling occurs between 
the supporting niche and stem cells, and the possibility 
exists that dysfunctional signaling by the supporting 
niche may drive CSC growth. Th  erefore, targeting the 
CSC niche with new therapeutic agents may disrupt 
these cellular communications and potentially interfere 
with CSC growth.
Cross-talk among embryonic signaling pathways
Th  e Hh, Notch, Wnt, and TGF-β signaling pathways, 
instead of acting as isolated units, may interact through 
cross-talk to provide tumor cells with an additional 
mechanism to evade chemotherapy (Figure 2) [29]. Th  e 
links between embryonic Hh signaling and EMT are 
relatively well established, but must also be considered in 
a context-dependent fashion as extensive evidence of 
cross-talk between the embryonic signaling pathways 
also occurs. Th   ese interlinked network communications 
may serve as a natural mechanism to increase cellular 
diversity to extracellular stimuli during embryogenesis 
and postnatal life. Th  e identiﬁ  cation of cross-talk net-
works in tumor cells may also allow for more eﬀ  ective 
design and use of combination anti-tumor therapies.
Th   e TGF-β signaling pathway is known to interact with 
the Wnt, Hh, and Notch pathways, as well as the 
mitogen-activated protein kinase (MAPK) pathway [30]. 
Th   ese interactions are complex, context dependent, and 
reﬂ   ective of the summary of all input signals. TGF-β 
signaling helps regulate a wide spectrum of cellular 
processes, including proliferation, diﬀ  erentiation, apop-
tosis, cell migration, and metastasis [31]. Understanding 
the consequences of TGF-β cross-talk with other signal-
ing pathways during tumorigenesis is key to developing 
eﬀ  ective therapeutic strategies.
Links between HER2 overexpression and activation of 
the phosphoinositide 3-kinase (PI3K)/Akt pathway 
suggests cross-talk between these pathways in breast 
tissue [32]. Treatment of sensitive HER2+ cell lines in 
vitro with trastuzumab led to decreased expression of 
both phospho-HER2 and phospho-Akt. In resistant 
HER2+ cells, trastuzumab treatment had no measurable 
eﬀ  ect on either HER2 or Akt phosphorylation.
A Notch binding sequence has been reported within the 
HER2 promoter and suggests a mechanism for Notch/
HER2 cross-talk [33]. HER2 expression was shown to be 
dependent upon Notch signaling in stem-like breast cells 
[34]. Inhibition, or silencing of Notch signaling, resulted 
in reduced HER2 expression by these cells. Th  us, 
combining Notch inhibitors with anti-HER2 agents may 
yield positive results in HER2+ breast cancer patients.
Also, cross-talk between Notch and the ER has been 
reported in breast cancer cell lines in vitro [35]. Estrogen 
was shown to inhibit Notch signaling through a mecha-
nism partly mediated by inhibition of Notch cleavage by 
γ-secretase. Treatment of ERα+  cell lines with anti-
estrogens (for example, estradiol) strongly upregulated 
Notch signaling and led to cell proliferation. Results 
indicated that Notch signaling may represent a thera-
peutic target in ERα- breast cancers. Conversely, combi-
nation therapies of Notch inhibitors and anti-estrogens 
may be eﬀ  ective in ERα+ breast cancers.
Notch signaling
Th  e Notch receptors and their ligands moderate short 
range cellular communications during proliferation, diﬀ  er-
entiation, embryogenesis and apoptosis [36]. Th  e  Notch 
receptors consist of non-covalently bound extracellular, 
transmembrane and intracellular domains. Notch recep-
tors interact with a diverse group of ligands from the 
Delta (-1, -3 and -4) and Serrate/Jagged families (-1 and 
-2). Receptor cleavage, with eventual release of the Notch 
intracellular domain (NICD), occurs through a 
disintegrin and metalloprotease (ADAM) followed by γ-
secretase cleavage. Once released from the membrane 
receptor, NICD translocates to the nucleus where it 
interacts with the CSL transcription factor to activate the 
Notch target genes such as HES, HEY and c-Myc [37]. 
Currently, γ-secretase and aspartyl protease serve as 
primary targets for Notch-speciﬁ  c investigational drug 
design.
Although cell type and context dependent, Notch 
signaling can lead to the initiation of EMT by activating 
nuclear factor-κB (NF-κB) or altering TGF-β signaling 
[38,39]. Th  e evolutionarily conserved Numb acts to 
regulate Notch activity by interacting with NICD, leading 
to NICD polyubiquitination and degradation [40]. 
Numb-mediated Notch inhibition is disrupted in 
approxi  mately 50% of breast carcinomas, due to degrada-
tion of Numb [41]. A relationship between overexpression 
of Notch signaling and poor overall survival in breast 
cancer patients has also been observed [42]. Most 
recently, Notch signaling was shown to have an important 
role in breast cancer bone metastasis pathophysiology. 
Notch signaling requires coordinated interaction with 
other pathways to induce EMT. During embryogenesis, 
Notch signaling coordinates Jagged 1, a Notch ligand, 
and HEY1, a Notch target gene, signaling in a Smad3-
dependent fashion [43].
TGF-β signaling
TGF-β signaling also plays a signiﬁ  cant role in the process 
of EMT, embryogenesis, and cancer patho  genesis. Key are 
the TGF-β-induced transcription factors Snail (SNAI1 and 
SNAI2/Slug), Twist (basic helix- loop- helix), Six family 
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(Figure 3). In breast CSCs, TGF-β signaling appears to 
modulate stem cell phenotype and maintain pluripotency 
[31,38,44,45]. TGF-β can alter tight junction formation in 
mammary epithelium and induce signaling in a number 
of embryonic signaling pathways, including Wnt, Notch, 
and Hh pathways. During EMT, SNAI1 and SNAI2/Slug 
(Snail) associate with SMAD3 and SMAD4 in the TGF-β 
signaling pathway to initiate cancer growth and 
metastasis by inhibiting or suppressing transcription of 
E-cadherin, occludin and claudin [46,47].
Hedgehog signaling
Th  e Hh ligands Sonic (SHh), Desert (DHh) and Indian 
(IHh), mediate embryogenesis by deﬁ  ning  polarity, 
morpho  genesis, proliferation and diﬀ  erentiation [48]. Hh 
signaling modulates tissue polarity and is responsible for 
stem cell maintenance. Th   e Hh ligands bind to a 12-pass 
transmembrane protein, Patched (PTCH) [49], and bind-
ing results in the de-repression of Smoothened (SMO) 
[50]. SMO then translocates to the primary cilium, which 
is then internalized and activated. Signaling then proceeds 
to activate the zinc-ﬁ  nger transcription factors GLI-1, -2 
Figure 3. Embryonic pathway signaling leads to induction of epithelial-to-mesenchymal transition. Hedgehog (Hh), Notch, Wnt, and 
transforming growth factor (TGF)-β signaling can activate epithelial-to-mesenchymal transition (EMT) regulators to induce phenotypic changes 
through a variety of signaling intermediates. EMT-inducing signals by Snail, Slug, KLF8, Twist, Goosecoid, Foxc1 and -2, or Zeb1 and -2 drive non-
mobile epithelial-like cells to acquire more invasive phenotypes. By migrating into the circulatory system, cancer stem cells can translocate to new 
locations and initiate new metastatic growths. EGF, epidermal growth factor; Fzd, Frizzled; Hh, Hedgehog; HIF, hypoxia-inducible factor; NICD, Notch 
intracellular domain; Smo, Smoothened; TGF, transforming growth factor.
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balance between the GLI-1 and -2 activators and the GLI-2 
and -3 repressor forms moderates Hh signaling [51].
EMT and metastases are blocked by SMO antagonists/
inhibitors in cell lines from pancreatic cancer [52,53]. For 
example, cyclopamine, a SMO antagonist, diminished 
motility and growth of cells [54,55]. Hh signaling plays a 
pivotal role in EMT by inducing the expression of a 
repressor of E-cadherin, SNAIL1 [56,57]. High GLI1 is 
seen in colorectal xenografts with high metastatic poten-
tial, epithelial morphology and EMT-associated markers 
[58]. In this model E-CADHERIN was also suppressed. 
While evaluating CSCs in the immunocompromised 
SCID mouse model is useful, it presents limitations for 
evaluating the role of the immune system, and in 
particular cytokines, in tumorigenesis and the develop-
ment of metastases.
Wnt/β-catenin signaling
Th   e Wnt signaling pathway controls development of the 
mammary gland during embryogenesis and growth and 
diﬀ   erentiation of the breast during pregnancy and 
lactation [59]. Currently there are 19 known Wnt genes, 
10 Frizzled (Fzd) receptors, and 2 low density lipoprotein 
receptor-related protein (LRP) co-receptors [60].
In the inactive state, cytoplasmic β-catenin is depleted 
from the cell via the destruction complex consisting of 
adenomatous polyposis coli (APC), glycogen synthase 
kinase 3β (GSK3β), Axin, and casein kinase-1α [61]. 
During Wnt signaling, activity of the destruction complex 
is inhibited, allowing accumulation and translocation of 
β-catenin to the nucleus, where it interacts with the 
lymphoid enhancer factor/T cell factor (Lef/Tcf) complex 
leading to targeted gene transcription.
Wnt signaling can be broadly grouped as either 
canonical/β-catenin or non-canonical. Canonical signal-
ing, the result of Wnt binding to Fzd, leads to β-catenin 
accumulation within the cell nucleus. β-catenin accumu-
lation within the nucleus or cytoplasm has been reported 
in approximately 50% of breast carcinomas and has been 
correlated with poor prognosis [62]. Non-canonical Wnt 
signaling does not result in β-catenin accumulation in the 
nucleus.
Tumor metastasis
Th  e dissemination of cancer cells may occur at an early 
stage of malignancy, but tumor cell dormancy, a time lag 
between tissue inﬁ   ltration and tumor formation, may 
result in metastatic latency [63,64]. Understanding the 
sequen  tial stepwise events during metastasis is essential 
for the development of novel therapeutic agents. However, 
considering the diﬀ  erences in target organs and rates of 
metastatic growth, optimizing therapeutic interventions 
remains challenging.
Th   e relationship between the niche microenvironment 
and metastasis was ﬁ  rst demonstrated by the charac  teri-
zation of bone marrow-derived cells that were directed to 
and colonized the pre-metastatic niche [65]. Th  e  recruit-
ment of bone marrow-derived cells to the pre-metastatic 
niche may involve a variety of secreted factors, including 
osteopontin [66]. Weakly metastatic human breast 
cancer cells could be induced to form metastatic tumors 
in mice when mixed with bone marrow-derived mesen-
chymal stem cells [67]. Induction of tumor formation was 
reversible and dependent on chemokine CCL5 
(RANTES) signaling through the CCR5 receptor. Th  ese 
studies suggest a link between cytokine concentrations in 
the stem cell microenvironment and induction of meta-
static tumor growth.
Gene expression studies performed on human breast 
cancer specimens have identiﬁ   ed a breast cancer 
molecular subtype ‘claudin-low’ population [68] that 
expresses an overlapping gene signature with that of CSC 
populations enriched with CD44+/CD24-/low cells using 
ﬂ  uorescence-activated cell sorting (FACS), and mammo-
spheres [69]. Claudin-low breast tumors are typically 
‘triple negative’ invasive, ductal carcinomas asso  ciated 
with a poor prognosis. Using genetically modi  ﬁ  ed cell 
lines, the ‘claudin-low’ population expressed low levels of 
Claudin 3 and E-cadherin and also expressed EMT 
markers such as vimentin and Twist, suggesting that 
claudin-low cells may have derived from immature 
progenitor or stem cells [70]. An EMT gene expression 
signature in human mammary epithelial cells, produced 
by overexpressing either Goosecoid (Gsc), Snail, Twist, 
or TGF-β1, or by knocking down expression of E-
cadherin, was found to be most similar to the gene 
expression signature found in claudin-low and meta-
plastic breast cancers. Th   e EMT signature most closely 
resembled the gene signature of basal B cell lines, 
characterized by high vimentin expression and a cancer 
stem cell-like proﬁ  le.
Epithelial-to-mesenchymal transition
Deregulation of EMT, an essential process during 
embryo  genesis and adult tissue repair and maintenance, 
may result in the mobilization and spread of primary 
tumor cells to distant locations. When adherent epithelial 
cells acquire mesenchymal properties, gene-expression 
patterns change and the cells acquire an increased 
motility potential. In the case of cancer, EMT and MET 
may serve to regulate cellular plasticity and play 
important roles during tumor invasion, metastasis, and 
therapeutic resistance [71].
EMT is also linked with the acquisition of stem cell 
characteristics [44]. Th   e concept of CSCs conferring both 
EMT and self-renewal properties provides the rationale 
for cancer cells to migrate and populate metastatic sites. 
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lation with anti-tumor therapies to inhibit metastasis.
Regulators of epithelial-to-mesenchymal transition
Th  e functional loss of E-cadherin is the most critical 
event linked with EMT. Th  e loss of these membrane 
adhesive proteins allows previously stationary tumor 
cells to dislodge from their original location and become 
more mobile. E-cadherin expression is controlled by 
various mechanisms, including inactivating mutations 
[72], epi  genetic modulation through promoter hyper-
methy  la  tion [73], and transcriptional repression by 
zinc-ﬁ  nger trans  cription factors with high aﬃ   nity for 
the E-box elements of E-cadherin promoter [74,75]. At 
the metastatic site, in the absence of additional EMT 
modulators in the stromal microenvironment, the cell 
transforms back to the original epithelial phenotype (via 
MET) [76]. Th   is important concept suggests that trans-
cription of the E-cadherin gene, or post-translational 
modiﬁ   cation, may be partly controlled by epigenetic 
mechanisms.
Epigenetic and DNA mutations
Hypermethylation and silencing of the E-cadherin pro-
moter is known to cause transcriptional down-regulation 
of the E-cadherin gene and is linked to the initiation of 
EMT, migration and invasion in breast cancer [73,77]. 
Reversibility of E-cadherin expression seems to be 
associated with the tumor progression and metastasis 
caused by EMT and MET [78]. Th  ese ﬁ  ndings demon-
strate that reduced E-cadherin expression may be linked 
with epigenetic modulation, due to partial methylation of 
the E-cadherin promoter region. More recently, a role of 
TGF-β has been identiﬁ  ed to maintain DNA methylation 
patterns during EMT and sustain the silencing of 
E-cadherin and other tight junction genes [79].
microRNAs
microRNAs (miRNAs) are a new class of EMT regulators, 
functioning to modify EMT-inducing transcription 
factors [80]. miRNAs act by inhibiting gene expression at 
the post-transcriptional level by suppression of sequence 
complementary mRNA targets [81]. Since each small 
inter  fering RNA can interact with dozens of target 
mRNAs, their impact on gene expression can be 
signiﬁ   cant. Members of the miR-200 family suppress 
tumor cell motility and invasiveness in vitro and inhibit 
induction of EMT through downregulation of ZEB1 and 
ZEB2 and the subsequent increase in E-cadherin 
expression [82]. Down-regulation of miR-200 was suﬃ   -
cient to reduce E-cadherin expression and induce EMT. 
Th   us, modulating the expression of particular miRNAs is 
likely to eﬀ   ect tumorigenesis and may play a role in 
tumor metastasis as well [83].
Th   e presence of miR-335 has been linked with 
suppression of metastasis in human breast cancer [84]. In 
a study of 20 primary human breast tumors, the expres-
sion of miR-335 was inversely associated with the forma-
tion of metastatic lesions. Results suggested that miR-335 
helped down-regulate metastatic genes in breast cancer, 
and the loss of miR-335 may serve as a negative 
prognostic indicator. Th  e important role that miRNAs 
play in the regulation of EMT suggests they may also 
serve as potential therapeutic targets.
Transcription factors
At least ten transcription factors have been identiﬁ  ed as 
EMT regulators during embryogenesis and/or carcino-
genesis (Figure 3) [56,85]. Besides ZEB1 and ZEB2, the 
following transcription factors directly repress the CDH1 
gene encoding E-cadherin: SNAI1, SNAI2 (SLUG), 
SNAI3, TWIST1, FOXC1, FOXC2, GSC (goosecoid), and 
KLF8. Extensive cross-talk among these transcription 
factors is necessary to maintain mesenchymal cell pheno-
types [85]. Furthermore, these EMT-inducing transcrip-
tion factors play a role in acquisition of stem cell charac-
teristics as these factors are expressed at much higher 
levels in CD44+/CD24- breast CSC-like cells than in more 
diﬀ  erentiated epithelial cells [44,86].
Bmi1
Th  e polycomb group protein Bmi-1 (B lymphoma Mo-
MLV insertion region 1 homologue) also plays a role in 
epigenetic gene-silencing and aﬀ  ects embryonic develop-
ment and oncogenesis [87]. Bmi-1’s role in breast cancer 
invasion and metastasis has been speculated, but details 
remain elusive. Recently, Song and colleagues [88] 
studied the Bmi-1 role in human nasopharyngeal 
epithelial cells and showed a direct association between 
Bmi1-1 and EMT. Th  is report also revealed that EMT 
induction was due to the direct binding of Bmi-1 to the 
phosphatase and tensin homologue (PTEN) locus caus-
ing down-regulated expression of PTEN. Subsequent 
activation of the PI3K/Akt pathway stabilized Snail and 
down-regulated E-cadherin. Bmi-1 may become a thera-
peutic target in CSCs, not only modulating the self-renewal 
potential of these cells, but also inhibiting EMT and 
preventing stem cells from acquiring invasive properties.
Immune regulation
In addition to its well known function for accelerating 
cell invasion, SNAI1 has been demonstrated to contribute 
to enhancing metastasis by inducing immunosuppression 
through multiple mechanisms [89]. SNAI1+ melanoma 
was observed to induce severe immunosuppression both 
in vitro and in vivo. In mice, enhanced tumor metastasis 
was achieved through suppression of nearly all antitumor 
eﬀ  ector cells at the local tumor site in vivo. Almost no 
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sion of SNAI1-induced EMT and immuno  sup  pression of 
the tumor-bearing host accelerate tumor metastasis 
simultaneously. Even tumors expressing low levels of 
SNAI1 might cause immunosuppression, suggest  ing that 
targeting SNAI1 may help prevent metastasis.
Epidermal growth factor receptor regulation
Expression of the ErbB receptor tyrosine kinase family 
and their ligands has been detected in various cancers 
and is particularly important in breast cancer, where it is 
associated with poor prognosis. Epidermal growth factor 
receptor (EGFR) signaling can induce EMT, invasion and 
metastasis via induction of Snail and ZEB [90]. EGFR/
ErbB2 heterodimers could induce mammary epithelial 
cells to acquire invasive properties [91]. Inhibition of 
ErbB receptor signaling reversed an aggressive inﬂ  amma-
tory breast cancer phenotype into an epithelial-like 
pheno type  in vitro [92]. Korkaya and colleagues [32] 
demonstrated that HER2 (ErbB2) stimulated the self-
renewal of breast cancer stem cells through the PI3K/Akt 
pathway. Th  eir study provided the therapeutic rationale 
to treat chemotherapy-resistant breast CSCs with the 
EGFR/HER2 inhibitor lapatinib [18]. Due to limited 
clinical eﬃ   cacy with ErbB inhibitors alone, a combination 
approach may provide improved clinical outcome.
Microenvironment and cytokines
Extracellular factors related to tumor microenvironment 
are known to induce EMT. For example, matrix metallo-
proteinase (MMP) family proteins were found to cause 
mammary epithelial cell invasion by inducing EMT 
[93,94]. It is likely that EMT-inducing signals are released 
by mesenchymal cells into the tumor microenvironment 
and confer on tumor cells invasive and metastatic 
characteristics [67]. Moreover, these signals are released 
by more activated and inﬂ  amed stroma surrounded by 
progressive tumors [76]. Th   e concept of activated stroma 
releasing EMT-inducing transcription factors into the 
microenvironment suggests that when tumor cells 
metastasize to distant sites, these stromal cells may not 
be activated. In the absence of EMT-inducing signals, the 
metastasized tumor cells may revert to their epithelial 
phenotype (MET). For example, Mori and colleagues [95] 
reported that mouse mammary epithelial cells underwent 
malignant transformation, including loss of cell-to-cell 
contact, when exposed to long-term oxidative stress.
Conclusion
Preventing the induction of EMT in primary breast 
cancer may serve as a novel mechanism to potentially 
inhibit the spread of metastatic disease. Activation of 
embryonic signaling pathways (that is, Notch, Wnt, Hh, 
and TGF-β) and their downstream transcription factors 
are responsible for driving EMT, resulting in the 
transformation of epithelial-like CSCs into cells with 
aggressive mesenchymal-like phenotypes. Th  ese  invasive 
CSCs have the potential to travel to distant sites and 
initiate metastatic tumors. Th  erapies directed towards 
inhibiting the induction of EMT may therefore reduce 
the formation of mesenchymal-like CSCs and improve 
clinical outcome.
In parallel with the development of this therapeutic 
approach, it is crucial to identify a more detailed 
molecular signature of the primary tumor in order to 
more accurately predict which patient population would 
beneﬁ  t from this type of long-term therapy. By examining 
embryonic pathway signaling at the tumor micro  environ-
mental level, one may better predict future metastatic 
potential. In high risk patients, therapeutic approaches 
directed at modulation of embryonic signaling pathways 
may be beneﬁ  cial.
Another promising approach to inhibit metastasis 
centers on developing molecular assays to identify which 
dormant tumor cells will acquire metastatic potential. 
Tumor dormancy is relatively unique to breast cancer as 
some disseminated tumor cells remain quiescent, while 
others metastasize to distant organs. For example, bone 
marrow micrometastases are commonly seen in early 
stage breast cancer. Targeting bone marrow disseminated 
tumors at an early stage with adjuvant therapy may be 
beneﬁ   cial to those with high risk for future distant 
metastasis. Alternatively, therapies designed to mobilize 
or stimulate dormant CSCs to undergo cell division may 
subsequently increase their sensitivity to currently 
available cytotoxic therapeutics.
Finally, the interrelationship between CSCs, embryonic 
signaling pathways, and EMT/MET oﬀ  ers a continuum 
of potential therapeutic targets. Knowledge of this 
relationship is important for both the researcher and 
clinician in developing and administering optimal 
therapies for breast cancer patients.
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